November 9, 2020 -- VUNO will attend RSNA 2020 to showcase the power of its flagship artificial intelligence (AI) radiology solutions, which have received the CE Mark and are currently being evaluated by the U.S. Food and Drug Administration under the 510(k) process.
As part of its ambitious plan to go global, VUNO is set to seize the opportunity of RSNA 2020 to further expand its networks with sales prospects and business partners from all around the world.
VUNO's exhibits at the RSNA show include the following:
VUNO's AI solutions are reshaping the medical industry, presenting a whole new level of experience to medical practitioners in their day-to-day workflow and enabling them to make diagnostic decisions faster and more accurately and provide quality patient care.
We are on a mission to "View the Invisible, Know the Unknown," and we will never rest until we discover the invisible and unknown territories of medicine by navigating ambiguity with the help of artificial intelligence.